Ian Bridges

2.1k total citations · 2 hit papers
31 papers, 1.5k citations indexed

About

Ian Bridges is a scholar working on Surgery, Economics and Econometrics and Immunology. According to data from OpenAlex, Ian Bridges has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Surgery, 15 papers in Economics and Econometrics and 7 papers in Immunology. Recurrent topics in Ian Bridges's work include Lipoproteins and Cardiovascular Health (21 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Pharmaceutical Economics and Policy (7 papers). Ian Bridges is often cited by papers focused on Lipoproteins and Cardiovascular Health (21 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Pharmaceutical Economics and Policy (7 papers). Ian Bridges collaborates with scholars based in United Kingdom, United States and Switzerland. Ian Bridges's co-authors include Scott M. Wasserman, Robert C. Scott, Frederick J. Raal, Evan A. Stein, Gang Li, Ransi Somaratne, Daniel Gaudet, David Sullivan, Lesley Burgess and Anders Olsson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Ian Bridges

29 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

2014 562 citations Frederick J. Raal, Evan A. Stein et al. The Lancet profile →
Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

2012 403 citations Frederick J. Raal, Robert C. Scott et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian Bridges United Kingdom	12	1.3k	557	321	203	198	31	1.5k
Ricardo Dent United States	20	1.6k 1.2×	684 1.2×	343 1.1×	234 1.2×	209 1.1×	41	2.0k
Patrick M. Moriarty United States	18	1.3k 1.0×	332 0.6×	349 1.1×	282 1.4×	190 1.0×	40	1.7k
Mahfouz El Shahawy United States	6	1.5k 1.1×	599 1.1×	397 1.2×	198 1.0×	258 1.3×	11	1.9k
Robert M. Stoekenbroek Netherlands	22	900 0.7×	218 0.4×	371 1.2×	188 0.9×	160 0.8×	43	1.3k
Daniel A. Gipe United States	13	1.7k 1.3×	577 1.0×	573 1.8×	447 2.2×	238 1.2×	24	2.1k
Sondra M. DePalma United States	6	733 0.6×	359 0.6×	267 0.8×	107 0.5×	57 0.3×	13	986
М. В. Ежов Russia	17	1.3k 1.0×	211 0.4×	431 1.3×	350 1.7×	261 1.3×	154	1.8k
Anastasia Lesogor Switzerland	14	701 0.5×	177 0.3×	304 0.9×	153 0.8×	117 0.6×	23	1.2k
Jonathan Fialkow United States	12	539 0.4×	224 0.4×	247 0.8×	86 0.4×	112 0.6×	29	1.0k
Laurens F. Reeskamp Netherlands	20	907 0.7×	136 0.2×	416 1.3×	335 1.7×	110 0.6×	65	1.4k

Countries citing papers authored by Ian Bridges

Since Specialization

Citations

This map shows the geographic impact of Ian Bridges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Bridges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Bridges more than expected).

Fields of papers citing papers by Ian Bridges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Bridges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Bridges. The network helps show where Ian Bridges may publish in the future.

Co-authorship network of co-authors of Ian Bridges

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Bridges. A scholar is included among the top collaborators of Ian Bridges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Bridges. Ian Bridges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jen, Min‐Hua, Shahrul Mt‐Isa, Haitao Chu, et al.. (2025). The Current Landscape of HTA Framework and Key Challenges. Statistics in Biopharmaceutical Research. 18(1). 64–78.

Rašlová, Katarı́na, Viera Doničová, Alexander Klabník, et al.. (2024). Detecting familial hypercholesterolemia: An observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia. Journal of clinical lipidology. 18(4). e537–e547. 2 indexed citations

Lehrke, Michael, Anja Vogt, Volker Schettler, et al.. (2024). Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in Therapy. 41(3). 1184–1200. 2 indexed citations

Ebenbichler, Christoph, Heinz Drexel, Ursula Hanusch, et al.. (2023). Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study. Wiener klinische Wochenschrift. 136(3-4). 77–86. 2 indexed citations

Díaz, García, Assumpta Caixàs, Núria Plana, et al.. (2023). Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study. Clínica e Investigación en Arteriosclerosis. 35(6). 263–271. 4 indexed citations

Gaudet, Daniel, Andrea Ruzza, Ian Bridges, et al.. (2022). Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 16(5). 676–684. 10 indexed citations

Wiegman, Albert, Andrea Ruzza, Raúl D. Santos, et al.. (2022). Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia. European Heart Journal. 43(Supplement_2). 2 indexed citations

Santos, Raúl D., Andrea Ruzza, G. Kees Hovingh, et al.. (2020). Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine. 383(14). 1317–1327. 115 indexed citations

Petrov, Ivo, Andreea Dumitrescu, Barak Zafrir, et al.. (2019). Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study. Advances in Therapy. 36(3). 608–620. 9 indexed citations

10.

Hovingh, G. Kees, Frederick J. Raal, Ricardo Dent, et al.. (2017). Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 11(6). 1448–1457. 48 indexed citations

11.

Sattar, N, Paul Valensi, David Preiss, et al.. (2016). Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies. Diabetologia. 59. 1 indexed citations

12.

Rosenson, Robert S., Terry A. Jacobson, David Preiss, et al.. (2016). Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovascular Drugs and Therapy. 30(3). 305–313. 23 indexed citations

13.

Raal, Frederick J., Evan A. Stein, Robert Dufour, et al.. (2014). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet. 385(9965). 331–340. 562 indexed citations breakdown →

14.

Bridges, Ian, Cynthia Christiano, Serge Cournoyer, et al.. (2013). Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrology Dialysis Transplantation. 28(5). 1241–1254. 38 indexed citations

15.

Rottembourg, Jacques, et al.. (2011). An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months. Clinical Nephrology. 75(3). 242–250. 1 indexed citations

16.

Feriani, Mariano, et al.. (2011). Extended dosing of darbepoetin alfa in peritoneal dialysis patients. BMC Nephrology. 12(1). 13–13. 6 indexed citations

17.

Galle, Jan, Kathleen Claes, István Kiss, et al.. (2011). An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrology Dialysis Transplantation. 27(6). 2303–2311. 4 indexed citations

18.

Macdougall, Iain C., Fernando Carrera, J. Braun, et al.. (2009). Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients. Clinical Nephrology. 71(4). 397–404. 11 indexed citations

19.

Cohen, Lee S., Cláudio N. Soares, Kimberly A. Yonkers, et al.. (2004). Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: A Double-Blind, Placebo-Controlled Trial. Psychosomatic Medicine. 66(5). 707–713. 52 indexed citations

20.

Cohen, Lee S., et al.. (2003). Paroxetine Controlled Release Is Effective in Treating Premenstrual Dysphoric Disorder*. Obstetrics and Gynecology. 101(Supplement). 111S–111S. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact